RIPK3 and inflammatory bowel disease: The vitamin D receptor (VDR) moves to the cytosol from the nucleus to stop RIPK1/RIPK3 from forming by binding to RIPK1, and this provides some theoretical support for an innovative approach to treating IBD in clinical settings [142].